About Us

TRIGR Therapeutics is a privately-owned company based in Irvine, California focused on the development and commercialization of novel therapeutics for unmet medical needs.

TRIGR is building an asset portfolio of clinical stage and pre-clinical antibodies that will represent the next wave in cancer immunotherapy. We currently have partnered with innovative R&D companies, such as ABL Bio in South Korea, and will develop selected ABL programs into approved immunotherapies worldwide. TRIGR’s diversified pipeline currently consists of immunotherapies against novel and validated targets that have the potential to overcome and modulate biological barriers (e.g. tumor micro-environment) to result in successful treatment outcomes.  George Uy, TRIGR founder and CEO: “It is TRIGR’s mission to identify and develop novel and paradigm-shifting immunotherapies addressing unmet medical needs and providing new treatment options to patients and their caregivers. Our immunotherapies are designed to TRIGR the patients’ immune system on our joint conquest to combating and defeating cancer.”

TRIGR strives to be a global pharmaceutical company while maintaining a focus on the Pacific Rim region for clinical and commercial development. We are in the process of assembling a world-class management team of industry veterans that is based in the US and China/Hong Kong and will execute on the efficient development of our immunotherapy programs.

George Uy

Chief Executive Officer & Founder

George started his career at F Hoffmann-La Roche in the Philippines. He later worked at Roche Basel and Roche China in senior executive positions on the commercial front. In the US, George was responsible for the commercial launch of breakthrough anti-cancer drugs like Xeloda® (Roche/Genentech) and Abraxane® (Abraxis Biosciences/Celgene). George also built up Commercial Operations at Spectrum Pharmaceuticals (Nasdaq: SPPI) and launched several of its oncology drugs. George was later Chief Commercial Officer of Sorrento Therapeutics (Nasdaq: SRNE) where he helped the company transition from the OTC market to Nasdaq and helped raised significant funding for the company. Sorrento’s clinical stage portfolio including the recently FDA-approved Ztlido®, RTX (phase 1/ 2 in intractable cancer pain and osteoarthritis), and  Cynviloq® (outlicensed to NantPharma after Phase 3 completion) were a result of George’s effort.

Miranda Toledano

Chief Finance Officer

Miranda Toledano joined TRIGR in August 2018. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) where she helped drive the strategies and operational infrastructure across each of the Company’s immuno-oncology, cellular therapy, and pain franchises. From 2012 to September 2016, Miranda served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.) where she completed equity capital market transactions totaling over $4 billion in aggregate value. Prior to joining MLV, Miranda served in the investment group of Royalty Pharma, a leading investment firm with over $15 billion in biotherapeutic royalty assets. From 1998 to 2003, Miranda led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Annie Fong, Ph.D.

Acting EVP Program Management & Development Operations

Annie has more than 18 years of biopharmaceutical industry experience in the therapeutic areas of oncology and inflammation. She managed R&D teams from selection of development candidates to Regulatory submissions for NCEs. While at Sugen, she was the program leader for the first small molecule inhibitor of angiogenesis to enter into the clinic. While at Exelixis (Nasdaq: EXEL), she was responsible for establishing Development operations and managing Development programs transforming this leader in model system genetics/genomics organization into a Development organization in Oncology therapeutics. While at Abraxis Biosciences, she managed all pipeline programs resulting in successful IND filings and clinical trial launches. Annie also has significant experience in strategic regulatory, development of protein therapeutics and devices. Annie received her Ph.D in Pharmacology from UCLA and her postdoctoral training at DNAX Research Institute of Molecular Biology and Immunology.

Board Members

George Uy

Chairman

George started his career at F Hoffmann-La Roche in the Philippines. He later worked at Roche Basel and Roche China in senior executive positions on the commercial front. In the US, George was responsible for the commercial launch of breakthrough anti-cancer drugs like Xeloda® (Roche/Genentech) and Abraxane® (Abraxis Biosciences/Celgene). George also built up Commercial Operations at Spectrum Pharmaceuticals (Nasdaq: SPPI) and launched several of its oncology drugs. George was later Chief Commercial Officer of Sorrento Therapeutics (Nasdaq: SRNE) where he helped the company transition from the OTC market to Nasdaq and helped raised significant funding for the company. Sorrento’s clinical stage portfolio including the recently FDA-approved Ztlido®, RTX (phase 1/ 2 in intractable cancer pain and osteoarthritis), and  Cynviloq® (outlicensed to NantPharma after Phase 3 completion) were a result of George’s effort.

Miranda Toledano

Member

Miranda Toledano joined TRIGR in August 2018. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) where she helped drive the strategies and operational infrastructure across each of the Company’s immuno-oncology, cellular therapy, and pain franchises. From 2012 to September 2016, Miranda served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.) where she completed equity capital market transactions totaling over $4 billion in aggregate value. Prior to joining MLV, Miranda served in the investment group of Royalty Pharma, a leading investment firm with over $15 billion in biotherapeutic royalty assets. From 1998 to 2003, Miranda led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Scientific Advisors

to follow